Axogen, Inc. AXGN

What this company does

Axogen, Inc. offers a portfolio of products for peripheral nerve repair, including Avance, an acellular nerve scaffold approved by the FDA for the treatment of patients with sensory, mixed and motor peripheral nerve discontinuities, and Avance Nerve Graft, a processed human nerve allograft used to bridge severed peripheral nerves. Its products are currently available in the United States, Canada, Germany, the United Kingdom, Spain and several other countries. In 2023, the company transferred Avance Nerve Graft tissue processing and packaging to its Axogen Processing Center facility, a 107,000 square foot building on approximately 8.5 acres of land located in Vandalia, Ohio. As of December 31, 2025, it had 138 direct sales professionals in the United States, and its direct sales force was supplemented by independent sales agencies that represented approximately 8% of its total revenue. As of December 31, 2025, the company had 622 employees, substantially all of whom were full-time.

Written from the business description in Axogen, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 24 February 2026. Every sentence was checked against that document before publication.